| Popis: |
Background Left ventricular GLS detects early subclinical ventricular disfunction in cardiac amyloidosis. Methods this study was performed according to the meta analysis of observational studies in epidemiology guidelines and with systematic search in the PubMed database from database inception until 1/10/2019, random effects meta analysis was used to find the prognostic and discriminatory performance of different GLS entities, publication bias was tested using begg's and eagers’ test and visualized by funnel plots, and meta regression was used to assess the sources of heterogeneity. Sensitivity analysis was used to assess the inclusion criteria of the study, the meta analysis software was StataCorp version 16, the primary outcome was echocardiographic changes and adverse cardiac events. Results of the 1600 records retrieved, a total of 12 studies fulfilled the inclusion criteria with a sample size of 1282 patients, mean age was 63.22 years, and 37.44 % were females with baseline LV ejection fraction of 55.9%, and baseline LV GLS -11.4 %, total deaths from all 12 studies were 570 patients (44.5%), from 4 included studies, heart failure was reported in 79 patients(38.3%), Hazard ratio: 1.197; 95%CI: (1.1388-1.2586), softwares used in this study were (GE: 6, TomTec: 3, Philips: 2, others: 1) the follow-up duration range(6-60 months). Conclusion Global longitudinal Strain can predict prognosis among patients with cardiac amyloidosis beyond left ventricle ejection fraction. GLS should be considered as a standard parameter along with the serum cardiac biomarkers when evaluating cardiac amyloidosis. |
Full Text from ScienceDirect